Rising Incidence of Hodgkin’s Lymphoma
According to the American Cancer Society, estimates for Hodgkin’s disease in the United States for 2017 were about 8,260 new cases (3,610 women and 4,650 men), and about 1,070 deaths (440 women and 630 men) from this cancer. Such an increase in number of new cases diagnosed every year, has been driving the Hodgkin’s lymphoma treatment market. The Lymphoma Research Foundation is spreading awareness on lymphoma, and is also funding the research and development required to eradicate lymphoma.
Adverse Long-term Side-effects of Treatment
The treatment of Hodgkin’s lymphoma is associated with physical side-effects. People who received treatment for Hodgkin’s lymphoma have an increased risk of developing other diseases and conditions later. The side-effects can also result from cancer therapy, as radiation therapy and chemotherapy can cause permanent damage in patients. For instance, radiation therapy to the pelvic area can cause infertility, unless the ovaries or testicles are shielded during treatment. Some people have a higher risk of developing secondary cancer, especially myeloid leukemia, lung cancer, or breast cancer. Radiation therapy to the neck area can cause problems in thyroid gland, most commonly, hypothyroidism. Chemotherapy can result in suppressed blood cell formation, leading to anemia. Chemotherapy drugs kill cancer cells, but they could result in damage of normal cells as well. Several chemotherapy drugs, particularly anthracyclines, can cause heart damage, which may increase the risk of heart failure, over time. In the developing countries, reimbursement is low, which may hinder the growth of the market.
North America to Dominate the Market
The Hodgkin’s Lymphoma treatment market has been segmented by treatment type and geography. By geography, it has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
Due to the presence of well-established healthcare facilities, North America dominates the Hodgkin’s Lymphoma treatment market. However, the Asia-Pacific segment is expected to register the highest CAGR over the forecast period, as government and private firms are making significant investments on the healthcare industry. Over the last couple of years, there have several mergers, acquisitions, and collaborations between companies, to invest in the Japanese market.
Key Developments in the Market
- October 2017 - FDA approved the second gene altering therapy Yescarta for the cancer. The therapy was approved for blood cancer and non-Hodgkin’s lymphoma.
- September 2017 - Aliqopa was approved by FDA, for the treatment of lymphoma.
Reasons to Purchase This Report
- Analysis of the global Hodgkin’s Lymphoma treatment market, with region-specific assessments and competition analysis on global and regional scales
- Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
- The treatment type that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support along with the Market Estimate sheet (in excel)
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increase Awareness About Hodgkin’s Lymphoma
6.1.2 Rising Incidence of Hodgkin’s Lymphoma
6.1.3 High Unmet Need in Older Patients and Patients with Relapsed or Refractory (R/R) Hl
6.2 Market Restraints
6.2.1 Adverse Long-Term Side Effects
6.2.2 High Cost of Treatment
6.4 Key Challenges
7. Market Segmentation
7.1 By Treatment Type
7.2 By Geography
7.2.1 North America
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
7.2.4 Middle East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East and Africa
220.127.116.11 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Bristol Myers Squibb Co.
9.2 F. Hoffmann-La Roche Ltd
9.3 Merck & Co. Inc.
9.4 Pfizer Inc.
9.5 4Sc Ag
9.6 Actinium Pharmaceuticals Inc.
9.7 Affimed Therapeutics AG
9.8 Incyte Corp.
9.9 Novartis AG
10. Future of the Market